Ítem
Solo Metadatos

Comparison of two doses of intravitreal bevacizumab (avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-up

Mostrar el registro sencillo de la publicación
dc.creatorWU, LIHTEHspa
dc.creatorAREVALO, J FERNANDOspa
dc.creatorROCA, JOSE A.spa
dc.creatorMAIA, MAURICIOspa
dc.creatorBERROCAL, MARIA H.spa
dc.creatorRODRIGUEZ, FRANCISCO J.spa
dc.creatorEVANS, TEODOROspa
dc.creatorCOSTA, ROGERIO A.spa
dc.creatorCARDILLO, JOSEspa
dc.date.accessioned2020-05-25T23:58:49Z
dc.date.available2020-05-25T23:58:49Z
dc.date.created2008spa
dc.description.abstractPURPOSE: To report the 6-month anatomical and visual outcomes after injecting two different doses of intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: An interventional, retrospective multicenter study of 45 eyes that were treated with at least one intravitreal injection (24 eyes, 1.25 mg; 21 eyes, 2.5 mg) of bevacizumab is reported. The main outcome measures were the central 1-mm macular thickness (CMT) and the change in ETDRS lines of best-corrected visual acuity (BCVA) at 6 months. RESULTS: Forty-five eyes were injected on average 26.1 months (range, 3-86 months) after the diagnosis. The average follow-up was 35.2 weeks (range, 24-52 weeks). All patients completed at least 6 months of follow-up. In the 1.25-mg dose group, at 1 month, there was an average gain of 4.5 lines of BCVA; at 3 months, 5.1 lines of BCVA; and at 6 months, 5.1 lines of BCVA (P less than 0.005). In the 2.5-mg dose group, at 1 month, there was an average gain of 2.3 lines of BCVA; at 3 months, 3.8 lines of BCVA; and at 6 months, 4.8 lines of BCVA (P = 0.05). In the 1.25-mg dose group, the mean CMT ± SD decreased from 461 ± 211 ?m at baseline to 321 ± 152 ?m at 1 month, 273 ± 99 ?m at 3 months, and 277 ± 114 ?m at 6 months (P = 0.0002). In the 2.5-mg group, the mean CMT ± SD decreased from 385 ± 168 ?m at baseline to 279 ± 111 ?m at 1 month, 249 ± 97 ?m at 3 months, and 240 ± 93 ?m at 6 months (P = 0.011). CONCLUSION: There were no statistically significant differences between the two dose groups with regard to the number of injections and anatomical and functional outcomes. Intravitreal injection of bevacizumab at doses up to 2.5 mg appears to be effective in improving BCVA and reducing CMT in BRVO in the short term. Multiple injections are needed in a large number of eyes for continued control of macular edema and preservation of visual acuity in the short term. Longer studies are needed to determine what role if any intravitreal injection of bevacizumab may play in the long-term treatment of this condition. © The Ophthalmic Communications Society, Inc.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1097/IAE.0b013e3181619bee
dc.identifier.issn15392864
dc.identifier.issn0275004X
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22934
dc.language.isoengspa
dc.relation.citationEndPage219
dc.relation.citationIssueNo. 2
dc.relation.citationStartPage212
dc.relation.citationTitleRetina
dc.relation.citationVolumeVol. 28
dc.relation.ispartofRetina, ISSN:15392864, 0275004X, Vol.28, No.2 (2008); pp. 212-219spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-42449094689&doi=10.1097%2fIAE.0b013e3181619bee&partnerID=40&md5=fae09616cc8adf73811c87dc35518318spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordoptical coherenceeng
dc.subject.keywordAngiogenesis inhibitorspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordMonoclonal antibodyspa
dc.subject.keywordVasculotropin aspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordArticlespa
dc.subject.keywordBranch retinal artery occlusionspa
dc.subject.keywordCiliary diskspa
dc.subject.keywordClinical articlespa
dc.subject.keywordClinical trialspa
dc.subject.keywordControlled studyspa
dc.subject.keywordDrug dose comparisonspa
dc.subject.keywordFemalespa
dc.subject.keywordHumanspa
dc.subject.keywordLaser coagulationspa
dc.subject.keywordMalespa
dc.subject.keywordMulticenter studyspa
dc.subject.keywordRetina macula edemaspa
dc.subject.keywordRetina neovascularizationspa
dc.subject.keywordTreatment outcomespa
dc.subject.keywordVisual acuityspa
dc.subject.keywordVitrectomyspa
dc.subject.keywordComparative studyspa
dc.subject.keywordDrug antagonismspa
dc.subject.keywordFluorescence angiographyspa
dc.subject.keywordFollow upspa
dc.subject.keywordInjectionspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordOptical coherence tomographyspa
dc.subject.keywordRetina macula edemaspa
dc.subject.keywordRetina vein occlusionspa
dc.subject.keywordRetrospective studyspa
dc.subject.keywordVitreous bodyspa
dc.subject.keywordAgedspa
dc.subject.keywordAngiogenesis inhibitorsspa
dc.subject.keywordAntibodieseng
dc.subject.keywordFemalespa
dc.subject.keywordFluorescein angiographyspa
dc.subject.keywordFollow-up studiesspa
dc.subject.keywordHumansspa
dc.subject.keywordInjectionsspa
dc.subject.keywordMacular edemaspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordRetinal vein occlusionspa
dc.subject.keywordRetrospective studiesspa
dc.subject.keywordTomographyeng
dc.subject.keywordTreatment outcomespa
dc.subject.keywordVascular endothelial growth factor aspa
dc.subject.keywordVisual acuityspa
dc.subject.keywordVitreous bodyspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordBranch retinal vein occlusionspa
dc.subject.keywordMacular edemaspa
dc.subject.keywordVascular endothelial growth factorspa
dc.titleComparison of two doses of intravitreal bevacizumab (avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-upspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos